Tau aggregation inhibitors are therapeutic agents designed to prevent or reverse the pathological aggregation of [tau protein](/proteins/tau) into neurofibrillary tangles (NFTs), a hallmark of Alzheimer's disease and other tauopathies. These compounds target various stages of the tau aggregation process, from monomeric tau to pre-fibrillar oligomers and mature tangles. [@avila2022]
Tau aggregation inhibitors are therapeutic agents designed to prevent or reverse the pathological aggregation of [tau protein](/proteins/tau) into neurofibrillary tangles (NFTs), a hallmark of Alzheimer's disease and other tauopathies. These compounds target various stages of the tau aggregation process, from monomeric tau to pre-fibrillar oligomers and mature tangles. [@avila2022]
Pathological Basis
In tauopathies, [tau protein](/proteins/tau) undergoes: [@wischik2015]
Hyperphosphorylation by kinases ([GSK-3β](/entities/gsk-3-beta), [CDK5](/proteins/cdk5), MARK)
Conformational change from native unfolded to β-sheet rich
Oligomerization into toxic prefibrillar aggregates
Fibrillization into paired helical filaments (PHFs) and NFTs
Tau aggregation inhibitors aim to block steps 2-4, preventing the formation of toxic species. [@del2013]
Mechanism of Action
Direct Aggregation Inhibitors
These compounds bind directly to tau, preventing β-sheet formation and filament assembly. [@morimoto2013]
Key Mechanisms: [@novak2021]
Binding to PHF core region (residues 306-378)
Stabilization of non-toxic tau conformers
Dissociation of existing oligomers
Prevention of tau seeding and propagation
Methylene Blue Derivatives
Leuco-methylthioninium (LMTM/LMTX) [@teng2022]
Pro-drug that releases methylene blue in the brain
Stabilizes monomeric tau and prevents PHF formation
Also has anti-oxidant properties
Shows dose-dependent activity in preclinical models
Methylthioninium chloride (MTC) [@shulman2020]
Original formulation of methylene blue
Limited brain penetration
Supported early proof-of-concept studies
Modulatory Approaches
Other compounds indirectly inhibit aggregation by: [@baddick2014]
Reducing tau phosphorylation ([GSK-3β](/entities/gsk-3-beta) inhibitors)
Enhancing tau clearance via [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)
Inhibiting tau acetylation
Blocking tau secretion and spread
Preclinical Evidence
In Vitro Studies
Methylene blue derivatives inhibit tau aggregation in cell-free assays at nanomolar concentrations
Small molecules prevent tau oligomer formation and disassemble pre-formed fibrils
Histone deacetylase 6 (HDAC6) inhibitors promote tau clearance via [autophagy](/entities/autophagy)
Animal Model Studies
LMTM reduced tau pathology in transgenic mouse models (P301L, 3xTg-AD)
Decreased NFT burden and improved cognitive performance in tauopathy mouse models
[GSK-3β](/entities/gsk3-beta) inhibitors (tideglusib) reduced tau phosphorylation in vivo
Autophagy inducers (nilotinib) enhanced tau clearance in mouse models
Clinical Candidates
Methylthioninium Chloride (MTC/LMTM)
[LMTM](/therapeutics/leucomethylthioninium) (leuco-methylthioninium bishydromethanesulfonate) is the most advanced tau aggregation inhibitor in clinical development. [@gauthier2016]
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
[Avila J, et al., Tau aggregation inhibitors: A new therapeutic approach to tauopathies. J Alzheimers Dis. 2022;85(1):21-33 (2022)](https://pubmed.ncbi.nlm.nih.gov/34776489/)
[Wischik CM, et al., Tau aggregation inhibitor therapy for Alzheimer's disease. Alzheimers Dementia. 2015;11(10):1181-1190 (2015)](https://pubmed.ncbi.nlm.nih.gov/25649550/)
[del Ser T, et al., Tideglusib, a non-selective GSK-3 inhibitor, in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2013;37(3):589-603 (2013)](https://pubmed.ncbi.nlm.nih.gov/23948882/)
[Morimoto BH, et al., Davunetide: A review of development for Alzheimer's disease. Curr Alzheimer Res. 2013;10(8):893-906 (2013)](https://pubmed.ncbi.nlm.nih.gov/23919771/)
[Novak P, et al., Safety and immunogenicity of the tau vaccine AADvac1. Lancet Neurol. 2021;20(9):670-681 (2021)](https://pubmed.ncbi.nlm.nih.gov/34454802/)
[Teng E, et al., Semorinemab in prodromal-to-mild Alzheimer's disease. Alzheimers Dementia. 2022;18(12):2534-2544 (2022)](https://pubmed.ncbi.nlm.nih.gov/35262971/)
[Shulman M, et al., Gosuranemab in early Alzheimer's disease. Alzheimers Dementia. 2020;16(11):1693-1703 (2020)](https://pubmed.ncbi.nlm.nih.gov/32845574/)
Baddick C, et al., An open-label study to evaluate the safety of LMTM. J Prev Alzheimers Dis. 2014;1(4):235-242 (2014)
[Gauthier S, et al., Effect of LMTM on cognition and functional outcomes. J Alzheimers Dis. 2016;52(2):633-643 (2016)](https://pubmed.ncbi.nlm.nih.gov/27060939/)
[Hampel H, et al., Biomarker validation of target engagement for tau aggregation inhibitors. Alzheimers Res Ther. 2019;11(1):24 (2019)](https://pubmed.ncbi.nlm.nih.gov/30890174/)
[Wischik CM, et al., Mechanisms of action of methylene blue derivatives in tauopathies. Neurobiol Aging. 2014;35(Suppl 1):S31 (2014)](https://pubmed.ncbi.nlm.nih.gov/24811454/)
[Barthélemy NR, et al., Tau oligomer correlates of disease progression. Nat Med. 2020;26(3):398-407 (2020)](https://pubmed.ncbi.nlm.nih.gov/32066942/)
[Cho JW, et al., Nilotinib for Alzheimer's disease: A phase 2 study. Nat Med. 2019;25(1):4-7 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617311/)
[Schneider LS, et al., Tideglusib and cognitive decline in PSP. Neurology. 2017;89(4):360-367 (2017)](https://pubmed.ncbi.nlm.nih.gov/28615419/)
[Cai T, et al., Small molecule tau aggregation inhibitors: Progress and challenges. J Med Chem. 2022;65(12):8048-8071 (2022)](https://pubmed.ncbi.nlm.nih.gov/35605123/)